INVIVO BioTech Services GmbH

PRODUCT INFORMATION

Anti-Spike (RBD) Antibody_AK3426

Description:

InVivo offers a series of different monoclonal antibodies for the detection of the Spike protein from SARS-CoV-2. All antibodies come from hybridoma cell lines that were generated by immunization with the recombinant full-length Spike protein (S) or the receptor-binding domain (RBD).

This antibody has been validated by ELISA and is specifically directed against an epitope that is located on the RBD. Additionally, ELISAs with directly coated antigens proved that this antibody also binds to Spike protein B.1.1.7 and different RBD variants (B.1.1.7, B.1.1.28.1, B.1.1.7 E484K and B.1.351).

It is also recommended and independently tested for use in sandwich ELISA assays.

All antibodies are produced exclusively under serum-free conditions from hybridoma and purified through one-step purification with Protein-A affinity chromatography.

Product-ID: AK3426

Host: Mouse

Clonality: Monoclonal

Isotype: lgG

Subclass: mlgG1k

Formulation: Liquid, PBS, pH 7.4, 0.2 μm sterile filtered

Concentration: $\geq 0.5 \text{ mg/ mL}$

Purity: ≥ 90% (via analytical CGE under reducing conditions)


Conjugate: Unconjugated

Specificity: S (tested for: Wuhan and B.1.1.7)

RBD (tested for: Wuhan, B.1.1.7, B.1.1.28.1, B.1.1.7 E484K and B.1.351)

The product is for research use or for further manufacturing only.

<u>Purity (analytical CGE, under reducing conditions):</u>



| Peak | Size [kDa] | % of Total | Observations |
|------|------------|--------------|--------------|
| 1 | 4.5 | 0.0 | Lower Marker |
| 2 | 5.5 | 0.0 | System Peak |
| 3 | 5.9 | 0.0 | System Peak |
| 4 | 6.9 | 0.0 | System Peak |
| 5 | 25.3 | Peak Value 1 | Light Chain |
| 6 | 56.6 | 0.4 | |
| 7 | 59.9 | Peak Value 2 | Heavy Chain |
| 8 | 70.0 | 0.4 | |
| 9 | 240.0 | 0.0 | Upper Marker |

Summation of peak values 1 and 2 results in a purity of ≥ 90%

Binding activity to SARS-CoV-2 Spike protein and receptor-binding domain variants (ELISA):

